Journal of Biomedical Science,
Journal Year:
2024,
Volume and Issue:
31(1)
Published: Jan. 12, 2024
Abstract
The
developments
of
antibodies
for
cancer
therapeutics
have
made
remarkable
success
in
recent
years.
There
are
multiple
factors
contributing
to
the
biological
molecule
including
origin
antibody,
isotype,
affinity,
avidity
and
mechanism
action.
With
better
understanding
progression
immune
manipulation,
recombinant
formats
used
develop
therapeutic
modalities
manipulating
cells
patients
by
targeting
specific
molecules
control
disease.
These
been
successful
minimizing
side
effects
instead
caused
small
or
systemic
chemotherapy
but
because
developing
resistance
against
these
antibodies,
combination
therapy
is
thought
be
best
bet
patient
care.
Here,
this
review,
we
discussed
different
aspects
affecting
their
efficacy
with
some
relevant
examples
most
studied
approved
US
FDA.
Innovative
approaches
in
the
design
of
T
cell-engaging
(TCE)
molecules
are
ushering
a
new
wave
promising
immunotherapies
for
treatment
cancer.
Their
mechanism
action,
which
generates
an
trans
interaction
to
create
synthetic
immune
synapse,
leads
complex
and
interconnected
relationships
between
exposure,
efficacy,
toxicity
these
drugs.
Challenges
thus
arise
when
designing
optimal
clinical
dose
regimens
TCEs
with
narrow
therapeutic
windows,
variety
dosing
strategies
being
evaluated
mitigate
key
side
effects
such
as
cytokine
release
syndrome,
neurotoxicity,
on-target
off-tumor
toxicities.
This
review
evaluates
current
optimization
throughout
preclinical
development
TCEs,
along
perspectives
improvement
strategies.
Quantitative
used
aid
understanding
dose-exposure-response
highlighted,
opportunities
guide
rational
next-generation
TCE
molecules,
optimize
their
patients.
Advanced Materials,
Journal Year:
2023,
Volume and Issue:
36(22)
Published: March 25, 2023
T-cell
immunotherapy
offers
outstanding
advantages
in
the
treatment
of
various
diseases,
and
with
selection
appropriate
targets,
efficient
disease
can
be
achieved.
has
made
great
progress,
but
clinical
results
show
that
only
a
small
proportion
patients
benefit
from
immunotherapy.
The
extensive
mechanistic
work
outlines
blueprint
for
using
T
cells
as
new
option
immunotherapy,
also
presents
challenges,
including
balance
between
different
fractions
cells,
inherent
suppression
patterns
microenvironment,
acquired
loss
decline
viability.
diversity,
flexibility,
intelligence
nanomedicines
give
them
potential
enhancing
Here,
how
strategies
adapted
nanomaterials
to
enhance
therapeutic
efficacy
is
discussed.
For
two
pathological
states,
immunosuppression
immune
activation,
recent
advances
diseases
such
cancers,
rheumatoid
arthritis,
systemic
lupus
erythematosus,
ulcerative
colitis,
diabetes
are
summarized.
With
focus
on
this
review
highlights
treatment,
helps
advance
one's
understanding
use
nanotechnology
Cell Reports Medicine,
Journal Year:
2023,
Volume and Issue:
4(10), P. 101199 - 101199
Published: Sept. 21, 2023
Cancer
immunotherapy
has
gained
traction
in
recent
years
owing
to
remarkable
tumor
clearance
some
patients.
Despite
the
notable
success
of
immune
checkpoint
blockade
(ICB)
multiple
malignancies,
engagement
system
for
targeted
prostate
cancer
(PCa)
therapy
is
still
its
infancy.
Multiple
factors
contribute
limited
response,
including
heterogeneity
PCa,
cold
microenvironment,
and
a
low
number
neoantigens.
Significant
effort
being
invested
improving
immune-based
PCa
therapies.
This
review
summary
status
treating
with
discussion
modalities,
vaccines,
adoptively
transferred
T
cells,
bispecific
cell
engagers,
which
are
undergoing
clinical
trials.
In
addition,
this
also
focuses
on
emerging
mechanism-based
small-molecule
tyrosine
kinase
inhibitors
modulatory
properties
that,
either
as
single
agents
or
combination
other
immunotherapies,
have
potential
improve
outcomes.
Journal of Biomedical Science,
Journal Year:
2024,
Volume and Issue:
31(1)
Published: Jan. 12, 2024
Abstract
The
developments
of
antibodies
for
cancer
therapeutics
have
made
remarkable
success
in
recent
years.
There
are
multiple
factors
contributing
to
the
biological
molecule
including
origin
antibody,
isotype,
affinity,
avidity
and
mechanism
action.
With
better
understanding
progression
immune
manipulation,
recombinant
formats
used
develop
therapeutic
modalities
manipulating
cells
patients
by
targeting
specific
molecules
control
disease.
These
been
successful
minimizing
side
effects
instead
caused
small
or
systemic
chemotherapy
but
because
developing
resistance
against
these
antibodies,
combination
therapy
is
thought
be
best
bet
patient
care.
Here,
this
review,
we
discussed
different
aspects
affecting
their
efficacy
with
some
relevant
examples
most
studied
approved
US
FDA.
